Toxicity profile and clinical outcomes in locally advanced head and neck cancer patients treated with induction chemotherapy prior to concurrent chemoradiation

  • Authors:
    • Eric C. Ko
    • Eric M. Genden
    • Krzysztof Misiukiewicz
    • Peter M. Som
    • Lale Kostakoglu
    • Chien-Ting Chen
    • Stuart Packer
    • Johnny Kao
  • View Affiliations

  • Published online on: October 21, 2011     https://doi.org/10.3892/or.2011.1512
  • Pages: 467-474
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The use of induction chemotherapy prior to chemoradiation for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) remains controversial. We explored whether toxicity from induction chemotherapy influenced the delivery of concurrent chemoradiation. Among 171 consecutive previously unirradiated patients with HNSCC treated with combined chemotherapy and radiation, we identified 66 patients with stage III-IVB head and neck carcinoma who were treated with induction chemotherapy prior to planned chemoradiation. The most common induction regimen was docetaxel, cisplatin and 5-FU (TPF; 80%) for 2 to 3 cycles. Mean radiation dose was 72 Gy (range, 36-75 Gy). Concurrent chemotherapy regimens included cisplatin (26%), cetuximab (5%) and 5-fluorouracil/hydroxyurea (65%)-based regimens. At a median follow-up of 27 months (range, 9-56 months), the 2-year locoregional control and distant control rates were 85 and 86%, respectively. The 2-year disease-free survival and overall survival rates were 74 and 80%, respectively. Although there were no grade 5 toxicities during induction chemotherapy, 26% of patients required hospitalization for adverse events, including 5% needing intensive care. The most common high grade adverse events were grade 4 neutropenia (21%) and neutropenic fever (17%). Six percent of patients were unable to tolerate concurrent chemotherapy. The 2-year disease-free survival was significantly higher in patients able to complete induction and concurrent chemoradiation as planned (83 vs. 27%, p<0.001). Induction chemotherapy followed by concurrent chemoradiation results in promising survival rates in our cohort of advanced head and neck carcinoma patients. Due to severe toxicities in a subset of patients, this strategy is only recommended in selected high-risk patients who are carefully followed by an experienced multidisciplinary team.

Related Articles

Journal Cover

February 2012
Volume 27 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ko EC, Genden EM, Misiukiewicz K, Som PM, Kostakoglu L, Chen C, Packer S and Kao J: Toxicity profile and clinical outcomes in locally advanced head and neck cancer patients treated with induction chemotherapy prior to concurrent chemoradiation. Oncol Rep 27: 467-474, 2012.
APA
Ko, E.C., Genden, E.M., Misiukiewicz, K., Som, P.M., Kostakoglu, L., Chen, C. ... Kao, J. (2012). Toxicity profile and clinical outcomes in locally advanced head and neck cancer patients treated with induction chemotherapy prior to concurrent chemoradiation. Oncology Reports, 27, 467-474. https://doi.org/10.3892/or.2011.1512
MLA
Ko, E. C., Genden, E. M., Misiukiewicz, K., Som, P. M., Kostakoglu, L., Chen, C., Packer, S., Kao, J."Toxicity profile and clinical outcomes in locally advanced head and neck cancer patients treated with induction chemotherapy prior to concurrent chemoradiation". Oncology Reports 27.2 (2012): 467-474.
Chicago
Ko, E. C., Genden, E. M., Misiukiewicz, K., Som, P. M., Kostakoglu, L., Chen, C., Packer, S., Kao, J."Toxicity profile and clinical outcomes in locally advanced head and neck cancer patients treated with induction chemotherapy prior to concurrent chemoradiation". Oncology Reports 27, no. 2 (2012): 467-474. https://doi.org/10.3892/or.2011.1512